Seizures are often the first manifestation of central nervous system dysfunction and are common in many inborn errors of metabolism, especially in neonates, infants, and children. A high index of suspicion is required to diagnose inborn errors of metabolism as the cause of seizures. It is also important to recognize these metabolic disorders early, as specific disease-modifying treatments are available for some with favorable long-term outcomes. This review discusses the classification of metabolic disorders as a cause of seizures based on pathogenesis and age and proposes a tiered approach for cost-effective diagnosis of metabolic disorders.
SuzukiYKureSOotaMHinoHFukudaM. Nonketotic hyperglycinemia: proposal of a diagnostic and treatment strategy. Pediatr Neurol. 2010;43:221–224.
6.
MourmansJMajoieCBBarthPGDuranMAkkermanEMPoll-TheBT. Sequential MR imaging changes in nonketotic hyperglycinemia. AJNR Am J Neuroradiol. 2006;27:208–211.
7.
Van HoveJLVande KerckhoveKHennermannJBBenzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005;28:651–663.
8.
DeodatoFBoenziSSantorelliFMDionisi-ViciC. Methylmalonic and propionic aciduria. Am J Med Genet C Semin Med Genet. 2006;142C:104–112.
9.
AgarwalRLMuranjanMN. Diagnostic practice for organic acidemias: barriers to early diagnosis. Arch Dis Child. 2008;93:1000.
10.
BunchMSinghA. Peculiar neuroimaging and electrophysiological findings in a patient with biotinidase deficiency. Seizure. 2011;20:83–86.
11.
SinghiPRayM. Ohtahara syndrome with biotinidase deficiency. J Child Neurol. 2011;26:507–509.
12.
SowellJPollardLWoodT. Quantification of branched-chain amino acids in blood spots and plasma by liquid chromatography tandem mass spectrometry for the diagnosis of maple syrup urine disease. J Sep Sci. 2011;34:631–639.
13.
LeeWT. Disorders of amino acid metabolism associated with epilepsy. Brain Dev. 2011;33:745–752.
14.
MillsPBStruysEJakobsCMutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12:307–309.
15.
SchmittBBaumgartnerMMillsPBSeizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52: e133–e142.
16.
GospeSM Jr. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. Curr Opin Neurol. 2006;19:148–153.
17.
BaynesKFariasSTGospeSMJr. Pyridoxine-dependent seizures and cognition in adulthood. Dev Med Child Neurol. 2003;45:782–785.
18.
KhayatMKormanSHFrankelPPNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism. Mol Genet Metab. 2008;94:431–434.
19.
MillsPBSurteesRAChampionMPNeonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet. 2005;14:1077–1086.
RuizAGarcia-VilloriaJOrmazabalAA new fatal case of pyridox(am)ine 5′-phosphate oxidase (PNPO) deficiency. Mol Genet Metab. 2008;93:216–218.
22.
GallagherRCVan HoveJLScharerGFolinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65:550–556.
23.
ManegoldCHoffmannGFDegenIAromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis. 2009;32:371–380.
24.
MullenSASulsADe JonghePBerkovicSFSchefferIE. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology. 2010;75:432–440.
25.
De VivoDCLearyLWangD. Glucose transporter 1 deficiency syndrome and other glycolytic defects. J Child Neurol. 2002;17(suppl 3):3S15–3S23; discussion 3S24-3S25.
26.
LeenWGKlepperJVerbeekMMGlucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133:655–670.
27.
LearyLDWangDNordliDRJrEngelstadKDe VivoDC. Seizure characterization and electroencephalographic features in Glut-1 deficiency syndrome. Epilepsia. 2003;44:701–707.
28.
SulsAMullenSAWeberYGEarly-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol. 2009;66:415–419.
29.
von MoersABrockmannKWangDEEG features of glut-1 deficiency syndrome. Epilepsia. 2002;43:941–945.
30.
ParolinGDrigoPToldoIPre- and postprandial electroencephalography in glucose transporter type 1 deficiency syndrome: an illustrative case to discuss the concept of carbohydrate responsiveness. J Child Neurol. 2011;26:103–108.
31.
KlepperJDiefenbachSKohlschutterAVoitT. Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins Leukot Essent Fatty Acids. 2004;70:321–327.
32.
WolfNIRahmanSSchmittBStatus epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features. Epilepsia. 2009;50:1596–1607.
33.
McCoyBOwensCHowleyRPartial status epilepticus—rapid genetic diagnosis of Alpers’ disease. Eur J Paediatr Neurol. 2011;15:558–562.
34.
GordonN. Alpers syndrome: progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol. 2006;48:1001–1003.
35.
NaviauxRKNguyenKV. POLG mutations associated with Alpers syndrome and mitochondrial DNA depletion. Ann Neurol. 2005;58:491.
36.
NguyenKVShariefFSChanSSCopelandWCNaviauxRK. Molecular diagnosis of Alpers syndrome. J Hepatol. 2006;45:108–116.
37.
EngelsenBATzoulisCKarlsenBPOLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 2008;131:818–828.
VisserNABraunKPvan den BerghWMJuvenile-onset Alpers syndrome: interpreting MRI findings. Neurology. 2010;74:1231–1233.
40.
BizziABugianiMSalomonsGSX-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8. Ann Neurol. 2002;52:227–231.
41.
SalomonsGSvan DoorenSJVerhoevenNMX-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am J Hum Genet. 2001;68:1497–1500.
42.
NasrallahFFekiMKaabachiN. Creatine and creatine deficiency syndromes: biochemical and clinical aspects. Pediatr Neurol. 2010;42:163–171.
43.
NasrallahFFekiMBriandGKaabachiN. GC/MS determination of guanidinoacetate and creatine in urine: a routine method for creatine deficiency syndrome diagnosis. Clin Biochem. 2010;43:1356–1361.
44.
HainsworthDPLiuGTHammCWKatzML. Funduscopic and angiographic appearance in the neuronal ceroid lipofuscinoses. Retina. 2009;29:657–668.
45.
GoebelHH. Morphological aspects of the neuronal ceroid lipofuscinoses. Neurol Sci. 2000;21: S27–S33.
46.
WilliamsREAbergLAuttiTGoebelHHKohlschutterALonnqvistT. Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochim Biophys Acta. 2006;1762:865–872.
47.
MoleSE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol. 2004;14:70–76.
48.
GoebelHHWisniewskiKE. Current state of clinical and morphological features in human NCL. Brain Pathol. 2004;14:61–69.
49.
NoskovaLStraneckyVHartmannovaHMutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet. 2011;89:241–252.
50.
ArsovTSmithKRDamianoJKufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am J Hum Genet. 2011;88:566–573.
51.
KohlschutterASchulzA. Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev. 2009;31:499–502.
YenCBeydounADruryI. Longitudinal EEG studies in a kindred with Lafora disease. Epilepsia. 1991;32:895–899.
60.
LescaGBoutry-KryzaNde ToffolBNovel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia. 2010;51:1691–1698.
61.
LohiHTurnbullJZhaoXCGenetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology. 2007;68:996–1001.
62.
AndradeDMAckerleyCAMinettTSSkin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology. 2003;61:1611–1614.
63.
CardinaliSCanafogliaLBertoliSA pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res. 2006;69:129–134.
64.
FaustPLBankaDSiriratsivawongRNgVGWikanderTM. Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain. J Inherit Metab Dis. 2005;28:369–383.
